Skip to main content

Table 1 Age, gender distribution of the 3 patient cohorts and the respective distribution of Aβ phases, Aβ-MTL phases, A-scores, Braak NFT-stage, CERAD neuritic plaque score, NIA-AA degree of AD pathology, diagnosis, PET-Aβ phase estimate, B-Aβ stage, B-Aβ plaque stage, Aβ load. Short description of the recruitment criteria of the cohorts and case selection criteria for this study

From: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

 Cohort 1Cohort 2Cohort 3
German casesLeuven cases[18F]flutemetamol phase 3 autopsy cases
Number of cases957997
Age in years (mean/range)72,43 (35–98)67,43 (34–90)80,86 (59–95)
male/female48/4754/2545/52
Aβ phase (mean/range)2,34 (0–5)1,8 (0–5)3,65 (0–5)
AβMTL phase (mean/range)1,96 (0–4)1,47 (0–5)2,92 (0–4)
A-score (mean/range)1,49 (0–3)1,18 (0–3)2,39 (0–3)
Braak NFT-stage (mean/range)2,11 (0–6)2,27 (0–6)3,95 (0–6)
CERAD neuritic plaque score (mean/range)0,53 (0–3)0,66 (0–3)1,86 (0–3)
NIA-AA degree of AD pathology (mean/range)1,11 (0–3)0,97 (0–3)2,01 (0–3)
Diagnosis (control/p-preAD/AD/AD+non-AD-D*/non-AD-D*)24/35/13/5/1818/4/15/8/343/8/33/28/25
PET-Aβ phase estimate (mean/range)n.a.n.a.1,81 (0–3)
Aβ load / % (mean/range)4,16 (0–23,34)n.a.6,75 (0–17,63)
B-Aβ stage (mean/range)1,42 (0–3) [n = 38]n.a.n.a.
B-Aβ plaque stage (mean/range)1,74 (0–3) [n = 70]n.a.n.a.
CAA severity grade (Vonsattel)1 (0–3)0,84 (0–3)1,51 (0–3)
CAA stage of topographical distribution1,1 (0–3)0,72 (0–3)1,64 (0–3)
CDR0,993 (0–3) [n = 88]1622 (0–3) [n = 74]n.a.
MMSEn.a.n.a.9,48 (0–30) [n = 65]
Scan-death intervaln.a.n.a.215 (0–846) days
Recruitment strategyHospital-based autopsiesMemory clinic-based cohortTerminally ill with life-expectancy of less than 3 years, ≥55 years of age, no pregnancy, no allergy against [18F]flutemetamol, physical status allows to undergo PET imaging
Case selection criteriaAβ phases, AβMTL phases and Aβ loads already determined in the context of previous studiesAβ phases and AβMTL phases already determined for biobank purposes[18F]flutemetamol amyloid PET images are available that allow the measurement of SUVRcort and SUVRcaud
  1. *Non-AD dementia (non-AD-D) includes cases with Lewy body disease, frontotemporal lobar degeneration with TDP43 (FTLD-TDP), fused in sarcoma (FTLD-FUS), or τ pathology (FTLD-tau: progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, Pick’s disease, and neurofibrillary tangle predominant dementia), encephalitis, Creutzfeldt-Jacob disease, tumor, vascular dementia and metabolic encephalopathy. These non-AD-D cases served as non-AD control cases from diseased brains to determine the differential diagnostic properties of the respective parameters